A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

NCT05312411 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Osteosarcoma

Interventions

BIOLOGICAL: SCRI-E2CAR_EGFRtv1
DRUG: UB_TT170

Sponsor

Seattle Children's Hospital

Collaborators

[object Object]